[go: up one dir, main page]

CN114502164A - 杂环化合物及其盐的应用 - Google Patents

杂环化合物及其盐的应用 Download PDF

Info

Publication number
CN114502164A
CN114502164A CN202080019479.7A CN202080019479A CN114502164A CN 114502164 A CN114502164 A CN 114502164A CN 202080019479 A CN202080019479 A CN 202080019479A CN 114502164 A CN114502164 A CN 114502164A
Authority
CN
China
Prior art keywords
hydrate
formula
ray powder
powder diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080019479.7A
Other languages
English (en)
Other versions
CN114502164B (zh
Inventor
刘喜宝
张红芬
李艳玲
马玉秀
吴希美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN114502164A publication Critical patent/CN114502164A/zh
Application granted granted Critical
Publication of CN114502164B publication Critical patent/CN114502164B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

式A所示杂环化合物、水合物、其药学上可接受的碱金属盐或者所述碱金属盐的水合物在制备治疗急性肺损伤或急性呼吸窘迫综合征药物中的用途。实验结果表明，上述化合物通过抑制巨噬细胞和嗜中性粒细胞向肺部的渗透，降低肺血管通透性，减少促炎性细胞因子和细胞因子趋化因子的产生和促进IL‑10的产生，极大地缓解了由香烟烟雾CS诱导或LPS诱导的急性肺损伤或急性呼吸窘迫综合征。
Figure DDA0003251013410000011

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080019479.7A 2019-05-22 2020-05-22 杂环化合物及其盐的应用 Expired - Fee Related CN114502164B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019104310264 2019-05-22
CN201910431026 2019-05-22
PCT/CN2020/091842 WO2020233713A1 (zh) 2019-05-22 2020-05-22 杂环化合物及其盐的应用

Publications (2)

Publication Number Publication Date
CN114502164A true CN114502164A (zh) 2022-05-13
CN114502164B CN114502164B (zh) 2024-01-26

Family

ID=73458373

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080019479.7A Expired - Fee Related CN114502164B (zh) 2019-05-22 2020-05-22 杂环化合物及其盐的应用

Country Status (2)

Country Link
CN (1) CN114502164B (zh)
WO (1) WO2020233713A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205749A1 (en) * 2003-03-13 2006-09-14 Yuzuru Abe Remedy and/or preventive for lung diseases
CN101896178A (zh) * 2007-10-10 2010-11-24 凯米科技公司 作为crth2受体拮抗剂的杂环化合物
US20150079105A1 (en) * 2012-03-30 2015-03-19 Ucl Business Plc Treatment of acute inflammation in the respiratory tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7205329B2 (en) * 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
GB0409921D0 (en) * 2004-05-04 2004-06-09 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205749A1 (en) * 2003-03-13 2006-09-14 Yuzuru Abe Remedy and/or preventive for lung diseases
CN101896178A (zh) * 2007-10-10 2010-11-24 凯米科技公司 作为crth2受体拮抗剂的杂环化合物
US20150079105A1 (en) * 2012-03-30 2015-03-19 Ucl Business Plc Treatment of acute inflammation in the respiratory tract

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S.SUZUKI ET AL: ""Critical role of the prostaglandin D2 receptor Crth2 in acute lung injury caused by lipopolysaccharide (LPS)-induced shock in mice"", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDCINE》, vol. 193 *
TAKAHISA MURATA ET AL: ""Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement"", vol. 110, no. 110, pages 5205 - 5210 *

Also Published As

Publication number Publication date
WO2020233713A1 (zh) 2020-11-26
CN114502164B (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
JP2012522803A5 (zh)
JP2020128376A5 (zh)
JP2021530565A5 (zh)
JP2013531598A5 (zh)
JP2018521121A5 (zh)
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JP2012507566A5 (zh)
JP2016065107A5 (zh)
JP2013540123A5 (zh)
JP2016065086A5 (zh)
JP2023002516A5 (zh)
JP2018158949A5 (zh)
JP2017531038A5 (zh)
JP2023109937A5 (zh)
JP2013538849A5 (zh)
JP2014530818A5 (zh)
JP2020521732A5 (zh)
CN115315423A (zh) 取代芳基类化合物
HRP20230813T1 (hr) Upadacitinib solni spoj i postupak njegove pripreme
CA2647346A1 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
JP2019151627A5 (zh)
WO2024100452A3 (en) Heterocyclic compounds as sting agonists
CN114502164A (zh) 杂环化合物及其盐的应用
JP2013516475A5 (zh)
GB2605894A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240126

CF01 Termination of patent right due to non-payment of annual fee